Trial will evaluate efficacy of combined drug-releasing balloon, self-expanding stent

  • July 26, 2014

Enrollment has started for the BIOLUX 4EVER trial, which will assess the combined use of a drug-releasing balloon and a self-expanding stent for the treatment of superficial femoral artery lesions, according to a press release.

The trial will enroll 120 patients who will receive both the Pulsar-18 self-expanding stent and the Passeo-18 Lux drug-releasing balloon (both Biotronik). The primary endpoint is primary patency at 12 months.

Full Story »

More »
More »
  • Blog
  • Dmitry Feldman MD
  • Eye on Intervention
  • Dmitriy N. Feldman, MD, discusses whether appropriate use criteria should guide reimbursement policies.
More »
More »
More »
More »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!